Neuroprotective Agents

• 

  Subject Areas on Research

  • A Double-Blind, Randomized, Placebo-Controlled Clinical Study of Trofinetide in the Treatment of Rett Syndrome. 
  • A novel therapeutic derived from apolipoprotein E reduces brain inflammation and improves outcome after closed head injury. 
  • A novel, efficient, randomized selection trial comparing combinations of drug therapy for ALS. 
  • A phase I/IIa clinical trial of a recombinant Rho protein antagonist in acute spinal cord injury. 
  • A prospective, multicenter, phase I matched-comparison group trial of safety, pharmacokinetics, and preliminary efficacy of riluzole in patients with traumatic spinal cord injury. 
  • A systematic review of methodology applied during preclinical anesthetic neurotoxicity studies: important issues and lessons relevant to the design of future clinical research. 
  • Activation of Nrf2 Pathway Contributes to Neuroprotection by the Dietary Flavonoid Tiliroside. 
  • Activation of metabotropic glutamate receptor subtype mGluR1 contributes to post-traumatic neuronal injury. 
  • Activation of the ATF6 (Activating Transcription Factor 6) Signaling Pathway in Neurons Improves Outcome After Cardiac Arrest in Mice. 
  • Acute N-Acetylcysteine Administration Ameliorates Loss of Olfactory Neurons Following Experimental Injury In Vivo. 
  • Acute ischemic stroke treatment in 2007. 
  • Allopregnanolone attenuates N-methyl-D-aspartate-induced excitotoxicity and apoptosis in the human NT2 cell line in culture. 
  • Amelioration strategies fail to prevent tobacco smoke effects on neurodifferentiation: Nicotinic receptor blockade, antioxidants, methyl donors. 
  • Amyotrophic lateral sclerosis: current practice and future treatments. 
  • An apoE-derived mimic peptide, COG1410, alleviates early brain injury via reducing apoptosis and neuroinflammation in a mouse model of subarachnoid hemorrhage. 
  • An overview of naturally occurring histone deacetylase inhibitors. 
  • Analysis of the brain bioavailability of peripherally administered magnesium sulfate: A study in humans with acute brain injury undergoing prolonged induced hypermagnesemia. 
  • Anesthetic neuroprotection: antecedents and an appraisal of preclinical and clinical data quality. 
  • Angiotensin protects cortical neurons from hypoxic-induced apoptosis via the angiotensin type 2 receptor. 
  • Antenatal magnesium sulfate and spontaneous intestinal perforation in infants less than 25 weeks gestation. 
  • Antipsychotic drugs: comparison in animal models of efficacy, neurotransmitter regulation, and neuroprotection. 
  • ApoE isoform-specific effects on LTP: blockade by oligomeric amyloid-beta1-42. 
  • Apolipoprotein E Exerts a Whole-Brain Protective Property by Promoting M1? Microglia Quiescence After Experimental Subarachnoid Hemorrhage in Mice. 
  • Apolipoprotein E Mimetic Peptide Increases Cerebral Glucose Uptake by Reducing Blood-Brain Barrier Disruption after Controlled Cortical Impact in Mice: An 18F-Fluorodeoxyglucose PET/CT Study. 
  • Apolipoprotein E mimetic peptide CN-105 improves outcome in a murine model of SAH. 
  • Apolipoprotein E protects against NMDA excitotoxicity. 
  • Apoptosis is not enhanced in primary mixed neuronal/glial cultures protected by isoflurane against N-methyl-D-aspartate excitotoxicity. 
  • Aptiganel hydrochloride in acute ischemic stroke: a randomized controlled trial. 
  • Argon Inhalation for 24 Hours After Onset of Permanent Focal Cerebral Ischemia in Rats Provides Neuroprotection and Improves Neurologic Outcome. 
  • Argon Inhalation for 24 h After Closed-Head Injury Does not Improve Recovery, Neuroinflammation, or Neurologic Outcome in Mice. 
  • Augmented methamphetamine-induced overflow of striatal dopamine 1 day after GDNF administration. 
  • BDNF mediates neuroprotection against oxygen-glucose deprivation by the cardiac glycoside oleandrin. 
  • Benzodiazepines protect hippocampal neurons from degeneration after transient cerebral ischemia: an ultrastructural study. 
  • Blockade of NAALADase: a novel neuroprotective strategy based on limiting glutamate and elevating NAAG. 
  • Brain natriuretic peptide improves long-term functional recovery after acute CNS injury in mice. 
  • CNS glucagon-like peptide-1 receptors mediate endocrine and anxiety responses to interoceptive and psychogenic stressors. 
  • COG1410 improves cognitive performance and reduces cortical neuronal loss in the traumatically injured brain. 
  • COG1410, a novel apolipoprotein E-based peptide, improves functional recovery in a murine model of traumatic brain injury. 
  • Cardiopulmonary bypass and the central nervous system: potential for cerebral protection. 
  • Central glucagon like peptide-1 delays solid gastric emptying via central CRF and peripheral sympathetic pathway in rats. 
  • Central nervous system complications of cardiac surgery. 
  • Changes in intracellular chloride after oxygen-glucose deprivation of the adult hippocampal slice: effect of diazepam. 
  • Chronic spinal cord electrical stimulation protects against 6-hydroxydopamine lesions. 
  • Coenzyme Q10: a review of its promise as a neuroprotectant. 
  • Con: Methylprednisolone is not indicated for patients during cardiopulmonary bypass. 
  • Concentration-Dependent Dual Role of Thrombin in Protection of Cultured Rat Cortical Neurons. 
  • Creatine and cyclocreatine attenuate MPTP neurotoxicity. 
  • Creatine for amyotrophic lateral sclerosis/motor neuron disease. 
  • Creatine for amyotrophic lateral sclerosis/motor neuron disease. 
  • Current management of glaucoma and the need for complete therapy. 
  • Developments in Neurovascular Diseases and Treatments. 
  • Diazepam, given postischemia, protects selectively vulnerable neurons in the rat hippocampus and striatum. 
  • Does NSAID use modify cognitive trajectories in the elderly? The Cache County study. 
  • Does minocycline have antidepressant effect? 
  • Does neurotropin-3 have a therapeutic implication in major depression? 
  • Effect of continuous infusion of asialoerythropoietin on short-term changes in infarct volume, penumbra apoptosis and behaviour following middle cerebral artery occlusion in rats. 
  • Effect of lipophilicity of Mn (III) ortho N-alkylpyridyl- and diortho N, N'-diethylimidazolylporphyrins in two in-vitro models of oxygen and glucose deprivation-induced neuronal death. 
  • Effect of pregabalin on cerebral outcome after cardiopulmonary bypass with deep hypothermic circulatory arrest in rats. 
  • Effect of the neuroprotective peptide davunetide (AL-108) on cognition and functional capacity in schizophrenia. 
  • Effects of NMDA receptor glycine recognition site antagonism on cerebral metabolic rate for glucose and cerebral blood flow in the conscious rat. 
  • Effects of a single dose of erythropoietin on subsequent seizure susceptibility in rats exposed to acute hypoxia at P10. 
  • Effects of creatine and cyclocreatine supplementation on kainate induced injury in pre-pubescent rats. 
  • Effects of postischemic halothane administration on outcome from transient focal cerebral ischemia in the rat. 
  • Effects of volatile anesthetics on N-methyl-D-aspartate excitotoxicity in primary rat neuronal-glial cultures. 
  • Electroencephalographic burst suppression is not required to elicit maximal neuroprotection from pentobarbital in a rat model of focal cerebral ischemia. 
  • Emerging disease-modifying therapies for the treatment of motor neuron disease/amyotropic lateral sclerosis. 
  • EndothelinA receptor antagonist BSF-208075 causes immune modulation and neuroprotection after stroke in gerbils. 
  • Estrogen mediates neuroprotection and anti-inflammatory effects during EAE through ERα signaling on astrocytes but not through ERβ signaling on astrocytes or neurons. 
  • Estrogen receptor-β ligand treatment after disease onset is neuroprotective in the multiple sclerosis model. 
  • Flupirtine blocks apoptosis in batten patient lymphoblasts and in human postmitotic CLN3- and CLN2-deficient neurons. 
  • GDNF protection against 6-OHDA-induced reductions in potassium-evoked overflow of striatal dopamine. 
  • Glycine antagonism does not block ischemic spontaneous depolarization in the rat. 
  • Have randomized controlled trials of neuroprotective drugs been underpowered? An illustration of three statistical principles. 
  • Hormone replacement therapy and ischemic stroke severity in women: a case-control study. 
  • Hormone therapy: physiological complexity belies therapeutic simplicity. 
  • In vivo models of cerebral ischemia: effects of parenterally administered NMDA receptor glycine site antagonists. 
  • Induction of Autophagy and Activation of SIRT-1 Deacetylation Mechanisms Mediate Neuroprotection by the Pomegranate Metabolite Urolithin A in BV2 Microglia and Differentiated 3D Human Neural Progenitor Cells. 
  • Ineffectiveness of burst suppression therapy in mitigating perioperative cerebrovascular dysfunction. Multicenter Study of Perioperative Ischemia (McSPI) Research Group. 
  • Inhibition of Blood-Brain Barrier Disruption by an Apolipoprotein E-Mimetic Peptide Ameliorates Early Brain Injury in Experimental Subarachnoid Hemorrhage. 
  • Interleukin-6 as a photoreceptor neuroprotectant in an experimental model of retinal detachment. 
  • Intraoperative magnesium administration does not improve neurocognitive function after cardiac surgery. 
  • Intrathecal administration of a novel apoE-derived therapeutic peptide improves outcome following perinatal hypoxic-ischemic injury. 
  • Intravenous magnesium sulfate does not increase ventricular CSF ionized magnesium concentration of patients with intracranial hypertension. 
  • Investigation of S-Nitrosoglutathione in stroke: A systematic review and meta-analysis of literature in pre-clinical and clinical research. 
  • Is age a key factor contributing to the disparity between success of neuroprotective strategies in young animals and limited success in elderly stroke patients? Focus on protein homeostasis. 
  • Is lithium neuroprotective? An updated mechanistic illustrated review. 
  • Ischemic stroke: "acidotoxicity" is a perpetrator. 
  • Isoflurane provides long-term protection against focal cerebral ischemia in the rat. 
  • Lacosamide improves outcome in a murine model of traumatic brain injury. 
  • Letter: Antiepileptogenic and neuroprotective effects of erythropoietin: recent data. 
  • Levetiracetam is neuroprotective in murine models of closed head injury and subarachnoid hemorrhage. 
  • Limitations of inferences from observational databases in amyotrophic lateral sclerosis: all that glitters is not gold. 
  • Long-term effects of excitatory amino acid antagonists NBQX and MK-801 on the developing brain. 
  • Long-term neuroprotection from a potent redox-modulating metalloporphyrin in the rat. 
  • Longitudinal Impact of Acute Spinal Cord Injury on Clinical Pharmacokinetics of Riluzole, a Potential Neuroprotective Agent. 
  • Magnesium efficacy in a rat spinal cord injury model. 
  • Magnesium neuroprotection is limited in humans with acute brain injury. 
  • Magnesium sulfate for neuroprotection in the setting of chorioamnionitis. 
  • Metallothionein in the central nervous system: Roles in protection, regeneration and cognition. 
  • Minocycline protects against neuronal mitochondrial dysfunction and cognition impairment. 
  • Multidimensional latent trait linear mixed model: an application in clinical studies with multivariate longitudinal outcomes. 
  • Multiple sclerosis patients' benefit-risk preferences: serious adverse event risks versus treatment efficacy. 
  • NMDA receptor antagonists ameliorate the stepping deficits produced by unilateral medial forebrain bundle injections of 6-OHDA in rats. 
  • NSAIDs and cognition in Alzheimer's disease. 
  • Neurobehavioral radiation mitigation to standard brain cancer therapy regimens by Mn(III) n-butoxyethylpyridylporphyrin-based redox modifier. 
  • Neuroprotection by N-methyl-D-aspartate antagonists in focal cerebral ischemia is dependent on continued maintenance dosing. 
  • Neuroprotection by nitrous oxide and xenon and its relation to minimum alveolar concentration. 
  • Neuroprotection from delayed postischemic administration of a metalloporphyrin catalytic antioxidant. 
  • Neuroprotection in cardiac surgery. 
  • Neuroprotection in subarachnoid hemorrhage. 
  • Neuroprotection is associated with beta-adrenergic receptor antagonists during cardiac surgery: evidence from 2,575 patients. 
  • Neuroprotection mediated through estrogen receptor-alpha in astrocytes. 
  • Neuroprotective effect of NMDA receptor glycine recognition site antagonism persists when brain temperature is controlled. 
  • Neuroprotective effect of curcumin in an experimental rat model of subarachnoid hemorrhage. 
  • Neuroprotective effects of NMDA receptor glycine recognition site antagonism: dependence on glycine concentration. 
  • Neuroprotective effects of creatine administration against NMDA and malonate toxicity. 
  • Neuroprotective effects of creatine and cyclocreatine in animal models of Huntington's disease. 
  • Neuroprotective effects of creatine in a transgenic animal model of amyotrophic lateral sclerosis. 
  • Neuroprotective effects of creatine in a transgenic mouse model of Huntington's disease. 
  • Neuroprotective effects of group III mGluR in traumatic neuronal injury. 
  • Neuroprotective effects of reactive oxygen species mediated by BDNF-independent activation of TrkB. 
  • Neuroprotective efficacy from a lipophilic redox-modulating Mn(III) N-Hexylpyridylporphyrin, MnTnHex-2-PyP: rodent models of ischemic stroke and subarachnoid hemorrhage. 
  • Neuroprotective pentapeptide CN-105 improves functional and histological outcomes in a murine model of intracerebral hemorrhage. 
  • Neuroprotective pentapeptide CN-105 is associated with reduced sterile inflammation and improved functional outcomes in a traumatic brain injury murine model. 
  • Neuroprotective therapy for acute ischaemic stroke: down, but not out. 
  • New in vitro model of traumatic neuronal injury: evaluation of secondary injury and glutamate receptor-mediated neurotoxicity. 
  • Nicotinamide pre-treatment ameliorates NAD(H) hyperoxidation and improves neuronal function after severe hypoxia. 
  • Nicotine is a developmental neurotoxicant and neuroprotectant: stage-selective inhibition of DNA synthesis coincident with shielding from effects of chlorpyrifos. 
  • No advantage of A beta 42-lowering NSAIDs for prevention of Alzheimer dementia in six pooled cohort studies. 
  • Non-cholinergic strategies for treating and preventing Alzheimer's disease. 
  • Novel Neuroprotective Potential of Crocin in Neurodegenerative Disorders: An Illustrated Mechanistic Review. 
  • OPTN is a host intrinsic restriction factor against neuroinvasive HSV-1 infection. 
  • Older Americans' risk-benefit preferences for modifying the course of Alzheimer disease. 
  • Patient safety in trials of therapy for acute ischemic stroke. 
  • Peripherally administered CRF stimulates colonic motility via central CRF receptors and vagal pathways in conscious rats. 
  • Pharmacology of riluzole in acute spinal cord injury. 
  • Phase 1 Randomized, Double-Blind, Placebo-Controlled Study to Determine the Safety, Tolerability, and Pharmacokinetics of a Single Escalating Dose and Repeated Doses of CN-105 in Healthy Adult Subjects. 
  • Pioglitazone in early Parkinson's disease: a phase 2, multicentre, double-blind, randomised trial. 
  • Postischemic inhibition of GABA reuptake by tiagabine slows neuronal death in the gerbil hippocampus. 
  • Potential neuroprotective effects of continuous topiramate therapy in the developing brain. 
  • Preliminary report of the effects of complement suppression with pexelizumab on neurocognitive decline after coronary artery bypass graft surgery. 
  • Prenatal choline deficiency does not enhance hippocampal vulnerability after kainic acid-induced seizures in adulthood. 
  • Prenatal choline supplementation protects against postnatal neurotoxicity. 
  • Prophylactic treatment with CN-105 improves functional outcomes in a murine model of closed head injury. 
  • Protective effect of 21-aminosteroid pretreatment in peripheral nerve low-load crush injury in mature and immature rats. 
  • Protective effect of apolipoprotein E-mimetic peptides on N-methyl-D-aspartate excitotoxicity in primary rat neuronal-glial cell cultures. 
  • Quality control autophagy: a joint effort of ubiquitin, protein deacetylase and actin cytoskeleton. 
  • REST and stress resistance in ageing and Alzheimer's disease. 
  • RNA aptamer-based functional ligands of the neurotrophin receptor, TrkB. 
  • Randomized, double-blinded, placebo controlled study of neuroprotection with lidocaine in cardiac surgery. 
  • Rapid loss of blood-brain barrier P-glycoprotein activity through transporter internalization demonstrated using a novel in situ proteolysis protection assay. 
  • Rasagiline for amyotrophic lateral sclerosis: A randomized, controlled trial. 
  • Relative neuroprotective effects of dizocilpine and isoflurane during focal cerebral ischemia in the rat. 
  • Repetitive intraperitoneal caspase-3 inhibitor and anesthesia reduces neuronal damage. 
  • Response to letter regarding article, "Intraoperative magnesium administration does not improve neurocognitive function after cardiac surgery". 
  • Riluzole for the treatment of acute traumatic spinal cord injury: rationale for and design of the NACTN Phase I clinical trial. 
  • Risuteganib Protects against Hydroquinone-induced Injury in Human RPE Cells. 
  • SAHIT Investigators--on the outcome of some subarachnoid hemorrhage clinical trials. 
  • SUMO1 Deficiency Exacerbates Neurological and Cardiac Dysfunction after Intracerebral Hemorrhage in Aged Mice. 
  • Safety and efficacy of riluzole in patients undergoing decompressive surgery for degenerative cervical myelopathy (CSM-Protect): a multicentre, double-blind, placebo-controlled, randomised, phase 3 trial. 
  • Safety and efficacy of rivastigmine in adolescents with Down syndrome: long-term follow-up. 
  • Selective gamma-aminobutyric acid type A receptor antagonism reverses isoflurane ischemic neuroprotection. 
  • Selective inhibition of kindling development by intraventricular administration of TrkB receptor body. 
  • Severe hypotension is not essential for isoflurane neuroprotection against forebrain ischemia in mice. 
  • Simvastatin treatment improves functional recovery after experimental spinal cord injury by upregulating the expression of BDNF and GDNF. 
  • Single-blind, placebo phase-in trial of two escalating doses of selegiline in the chronic fatigue syndrome. 
  • Statins and ischemic stroke severity: cytoprotection. 
  • Statins improve outcome in murine models of intracranial hemorrhage and traumatic brain injury: a translational approach. 
  • Stroke Treatment Academic Industry Roundtable (STAIR) recommendations for maximizing the use of intravenous thrombolytics and expanding treatment options with intra-arterial and neuroprotective therapies. 
  • Study protocol for a randomised, double-blind, placebo-controlled study evaluating the Efficacy of cannabis-based Medicine Extract in slowing the disease pRogression of Amyotrophic Lateral sclerosis or motor neurone Disease: the EMERALD trial. 
  • TRPing into excitotoxic neuronal death. 
  • Targeting the SUMO pathway for neuroprotection in brain ischaemia. 
  • Ten years and counting: moving leucine-rich repeat kinase 2 inhibitors to the clinic. 
  • The BET-Bromodomain Inhibitor JQ1 Reduces Inflammation and Tau Phosphorylation at Ser396 in the Brain of the 3xTg Model of Alzheimer's Disease. 
  • The MARBLE Study Protocol: Modulating ApoE Signaling to Reduce Brain Inflammation, DeLirium, and PostopErative Cognitive Dysfunction. 
  • The NeuroAiD II (MLC901) in vascular cognitive impairment study (NEURITES). 
  • The indolocarbazole Gö6976 protects neurons from lipopolysaccharide/interferon-gamma-induced cytotoxicity in murine neuron/glia co-cultures. 
  • The injured cochlea as a target for inflammatory processes, initiation of cell death pathways and application of related otoprotectives strategies. 
  • The microtubule interacting drug candidate NAP protects against kainic acid toxicity in a rat model of epilepsy. 
  • The neuroprotective effect of xenon administration during transient middle cerebral artery occlusion in mice. 
  • The non-haematopoietic biological effects of erythropoietin. 
  • The novel apolipoprotein E-based peptide COG1410 improves sensorimotor performance and reduces injury magnitude following cortical contusion injury. 
  • The protective profile of argon, helium, and xenon in a model of neonatal asphyxia in rats. 
  • Therapeutic Development of Apolipoprotein E Mimetics for Acute Brain Injury: Augmenting Endogenous Responses to Reduce Secondary Injury. 
  • Therapeutic implications of estrogen for cerebral vasospasm and delayed cerebral ischemia induced by aneurysmal subarachnoid hemorrhage. 
  • Usefulness of the postkainate spontaneous recurrent seizure model for screening for antiseizure and neuroprotective effects. 
  • Using lithium as a neuroprotective agent in patients with cancer. 
  • Vascular endothelial growth factor rescues hippocampal neurons from glutamate-induced toxicity: signal transduction cascades. 
  • What constitutes clinical evidence for neuroprotection in Alzheimer disease: support for the cholinesterase inhibitors? 
  • Xenon and sevoflurane provide analgesia during labor and fetal brain protection in a perinatal rat model of hypoxia-ischemia. 
  • Xenon attenuates cardiopulmonary bypass-induced neurologic and neurocognitive dysfunction in the rat. 
  • Xenon for traumatic brain injury: a noble step forward and a wet blanket. 
  • Xenon neuroprotection in experimental stroke: interactions with hypothermia and intracerebral hemorrhage. 
  • [Investigation of neuroprotective activity of apolipoprotein E peptide mimetic Cog1410 in transgenic lines of Drosophila melanogaster]. 
  • gamma-Aminobutyric acid(A) neurotransmission and cerebral ischemia. 
  • mGluR modulation of post-traumatic neuronal death: role of NMDA receptors. 
  • pH-sensitive NMDA inhibitors improve outcome in a murine model of SAH. 
• 

  Keywords of People

  • Doraiswamy, P. Murali, Professor of Psychiatry and Behavioral Sciences, Duke Science & Society
  • James, Michael Lucas, Associate Professor of Anesthesiology, Anesthesiology
  • Laskowitz, Daniel Todd, Professor of Neurology, Duke Science & Society
  • Muir, Kelly Walton, Associate Professor of Ophthalmology, Ophthalmology, Glaucoma
  • Schwartz-Bloom, Rochelle D., Professor Emeritus of Pharmacology & Cancer Biology, Duke Science & Society